Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
34 hedge funds and large institutions have $77.3M invested in Sinovac Biotech, Ltd in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 14 closing their positions.
4,167% more call options, than puts
Call options by funds: $128K | Put options by funds: $3K
7% more capital invested
Capital invested by funds: $72.5M → $77.3M (+$4.83M)
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
15% less funds holding
Funds holding: 40 → 34 (-6)
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$1.7M |
| 2 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
+$1.11M |
| 3 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
+$313K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$245K |
| 5 |
OTC
Opera Trading Capital
Paris,
France
|
+$217K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$6.24M |
| 2 |
First Manhattan
New York
|
-$193K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$151K |
| 4 |
FIM
Freedom Investment Management
Hartford,
Connecticut
|
-$133K |
| 5 |
Morgan Stanley
New York
|
-$121K |
SVA Hedge Fund Activity: Q1 2016 in Review
34 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q1 2016, worth a combined $77.3M — up 6.7% from $72.5M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of SVA and 8 opened new positions — a net loss of 6 holders — while 11 trimmed existing stakes and 11 added.
The largest buyer was Citigroup, opening a new position worth an estimated $1.7M. The largest seller was Fidelity International, exiting entirely with an estimated $6.24M sold.
- 34 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q1 2016, down from 40 in Q4 2015.
- Funds reported $77.3M of Sinovac Biotech, Ltd stock for Q1 2016, up 6.7% quarter-over-quarter.
- 8 funds opened new Sinovac Biotech, Ltd positions in Q1 2016 and 14 closed out, a net change of -6 holders.
- The largest Sinovac Biotech, Ltd buyer in Q1 2016 was Citigroup, an estimated $1.7M added.
- The largest Sinovac Biotech, Ltd seller in Q1 2016 was Fidelity International, an estimated $6.24M sold.
Based on aggregated 13F filings for Q1 2016.